Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
378
-
Total 13F shares, excl. options
-
55.4M
-
Shares change
-
-385K
-
Total reported value, excl. options
-
$2.25B
-
Value change
-
-$39.6M
-
Put/Call ratio
-
0.92
-
Number of buys
-
157
-
Number of sells
-
-184
-
Price
-
$40.65
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2022
489 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2022.
CRISPR Therapeutics AG - Common Stock (CRSP) has 378 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.4M shares
of 86M outstanding shares and own 64.39% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (7.83M shares), Capital International Investors (5.35M shares), Sumitomo Mitsui Trust Holdings, Inc. (4.01M shares), Nikko Asset Management Americas, Inc. (4.01M shares), T. Rowe Price Investment Management, Inc. (2.99M shares), BlackRock Inc. (2.63M shares), FMR LLC (2.18M shares), STATE STREET CORP (2.08M shares), NEA Management Company, LLC (1.59M shares), and VANGUARD GROUP INC (1.44M shares).
This table shows the top 378 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.